During Covid-19, a wave of companies globally—from pharmaceutical giants to tech platforms like Zoom and even a fitness company like Peloton—experienced an unprecedented surge in revenue and share prices. In India, too, pharma and diagnostics firms, e-commerce, edtech, fintech and payment companies, OTT platforms, and data services firms saw a boom.
But as the world recovered, many of these pandemic-era market darlings faced a reckoning. Revenues dipped, demand normalised, and business momentum faltered.
In India, the most prominent symbol of the Covid response was the Serum Institute of India. The company became the world’s largest Covid vaccine supplier (Covishield), propelling it, and CEO Adar Poonawalla, to record revenues and global recognition.
Yet, like others, Serum too has faced a post-Covid reset, forcing it to reinvent, as Neetu Chandra Sharma writes…